Oxford BioDynamics Plc (LON:OBD – Get Free Report) shares hit a new 52-week low during trading on Thursday . The company traded as low as GBX 0.15 and last traded at GBX 0.17, with a volume of 6221344 shares trading hands. The stock had previously closed at GBX 0.17.
Oxford BioDynamics Stock Performance
The firm has a market cap of £7.34 million, a P/E ratio of -0.21 and a beta of 0.42. The company’s 50 day moving average is GBX 0.19 and its two-hundred day moving average is GBX 0.23. The company has a debt-to-equity ratio of 457.97, a current ratio of 0.88 and a quick ratio of 2.80.
Oxford BioDynamics Company Profile
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Read More
- Five stocks we like better than Oxford BioDynamics
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
